

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	09/936,362
		Filing Date	2001-12-19
		First Named Inventor	S. Loosmore
		Art Unit	1645
		Examiner Name	Jennifer E. Graser
Sheet	1	of	2
Attorney Docket No: 1038-1190 MIS:JB			

US PATENT DOCUMENTS					
Exami ner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,549,897	08-27-1996	Barenkamp, et al.	Entire document
	A2	5,603,938	02-18-1997	Barenkamp, et al.	Entire document
	A3	5,646,259	07-08-1997	St. Geme, et al.	Entire document
	A4	5,869,065	02-09-1999	Barenkamp, et al.	Entire document
	A5	5,869,302	02-09-1999	Loosmore, et al.	Entire document
	A6	5,925,362	07-20-1999	Spitler, et al.	Entire document
	A7	6,153,406	11-28-2000	Tai, et al.	Entire document
	A8	6,218,141	04-17-2001	Barenkamp, et al.	Entire document
	A9	6,342,232	01-29-2002	Loosmore, et al.	Entire document
	A10	6,432,669	08-13-2002	Loosmore, et al.	Entire document
	A11	6,974,581	12-13-2005	Loosmore, et al.	Entire document
	A12	7,118,749	10-10-2006	Loosmore, et al.	Entire document

FOREIGN PATENT DOCUMENTS						
Exami ner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	B1	WO 00/51633A3	09-08-2000	Connaught Laboratories Ltd.	Entire document	
	B2	WO 00/35477A3	06-22-2000	Connaught Laboratories Ltd.	Entire document	
	B3	EP1903055A3	08-06-2008	Sanofi Pasteur Limited	Entire document	
	B4	EP2133359A3	03-10-2010	Sanofi Pasteur Limited	Entire document	
	B5	EP09170138.3 search report	02-05-2010	Sanofi Pasteur Limited	Entire document	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
	C1	BERNARDEZ CLARK, et al. Refolding of recombinant proteins. Curr. Op. Biotech. 9: 157-63 (1998)	
	C2	LOOSMORE, et al. The Haemophilus influenzae HtrA protein is a protective antigen. Inf. Immun. 66(3): 899-906 (1998)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/936,362
				Filing Date	2001-12-19
				First Named Inventor	S. Loosmore
				Art Unit	1645
				Examiner Name	Jennifer E. Graser
Sheet	2	of	2	Attorney Docket No: <b>1038-1190 MIS:JB</b>	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C3	YANG, et al. A 20-kilodalton N-terminal fragment of the D15 protein contains a protective epitope(s) against Haemophilus influenzae type a and type b. Inf. Immun. 66(7): 3349-3354 (1998)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.